Skip to content
★ Sign in to follow
Jiangsu Nhwa Pharmaceutical Co., Ltd logo

Jiangsu Nhwa Pharmaceutical Co., Ltd Stock: price and insider trades · China

恩华药业

CN·Mcap CN¥22BHealth Care

No insider purchase over the last 90 days. The latest, by 孙彭生, was filed 22 Apr 2026.

Jiangsu Nhwa Pharmaceutical Co., Ltd: what insiders have been doing

Jiangsu Nhwa Pharmaceutical Co., Ltd is a Health Care company. Its directors and officers file their transactions with SSE / SZSE (CSRC). The last twelve months, up to 4 November 2026, brought 1 filing signed by 1 insider.

No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €534k, made by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 孙彭生 filed the largest purchase, €534k, on 22 April 2026. Those buying include 1 board member.

With 1 filing in twelve months, the company is quieter than the median of 2 filings across the 521 companies we follow on the same exchange. Since 2025, the database holds 2 purchases and no sales by insiders of the company.

The most recent open-market purchase was published on 22 April 2026, 200 days ago.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
孙彭生2 buys

Since the insiders bought

  • Filed 22 Apr 2026 · 200 days ago · €534k
    +4.9%
    Entry CN¥21.37 · Close 03 Nov 2026 CN¥22.41

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 5,308 of 26,912 companies
67.2
score / 100
Value
49
Quality
85
FCF yld2.9%
Earn yld4.8%
EV/EBITDA16.1x
ROE14%
Gross mgn72%
Net mgn18%
Debt/EBITDA0.0x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥21.73
Analyst consensus
3 analysts
1.67/5
CN¥26.00Target CN¥28.11(+29%)CN¥30.00
Income statement
RevenueCN¥5.9B
Gross profitCN¥4.3B72% margin
EBITDACN¥1.4B23% margin
Net incomeCN¥1.1B17.9% margin
Valuation
PER (trailing)19.9x
PER (forward)16.2x
P/Book2.6x
Beta-0.30
Balance sheet & cash
Market capCN¥22B
Total debtCN¥67.7M
Free Cash FlowCN¥641M
Debt / Equity1%
Profitability & ownership
ROE13.7%
ROA7.9%
% insiders51.6%
% institutions11.0%
Last declaration on 22 April 2026
Declarations2 total
  • ▲
    董事Executives
    4M CNY12SZSE
    200,000 shares47.0% of flowA股XSHESZSE:273000000493900220
    Canonical exit: 21 Jul 2026 (T+90)
  • ▲
    董事Executives
    5M CNY12SZSE
    237,900 shares53.0% of flowA股XSHESZSE:173000009104650800
    Canonical exit: 14 Sept 2025 (T+90)

2 of 2 declarations

About Jiangsu Nhwa Pharmaceutical Co., Ltd

恩华药业 is a company specializing in the health and pharmaceutical sector, offering a range of pharmaceutical products. It is listed on the XSHE market.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations